Cargando…
Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis
Bacterial conjunctivitis, commonly known as pink eye, is demographically unbiased in its prevalence and can be caused by a variety of aerobic and anaerobic bacteria. Timely empiric treatment with a broad-spectrum anti-infective, such as a topical fluoroquinolone, is critical in preventing potentiall...
Autores principales: | Comstock, Timothy L, Karpecki, Paul M, Morris, Timothy W, Zhang, Jin-Zhong |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2861926/ https://www.ncbi.nlm.nih.gov/pubmed/20463787 |
Ejemplares similares
-
Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
por: Silverstein, Bruce E, et al.
Publicado: (2012) -
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes
por: Morris, Timothy W, et al.
Publicado: (2011) -
Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
por: Haas, Wolfgang, et al.
Publicado: (2011) -
Besifloxacin Ophthalmic Suspension: Emerging Evidence of its Therapeutic Value in Bacterial Conjunctivitis
por: Khimdas, S., et al.
Publicado: (2011) -
The Safety of Besifloxacin Ophthalmic Suspension 0.6 % Used Three Times Daily for 7 Days in the Treatment of Bacterial Conjunctivitis
por: Malhotra, Ranjan, et al.
Publicado: (2013)